amycretin subcutaneous (NN9487 SC) / Novo Nordisk - LARVOL DELTA

A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function (clinicaltrials.gov) - P1 | N=42 | Completed | Sponsor: Novo Nordisk A/S | Recruiting ➔ Completed

Trial completion • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Renal Disease • Type 2 Diabetes Mellitus

A Research Study Looking at How the Compound NNC0487-0111 Works With Birth Control Pills and Affects Emptying of the Stomach in Women Not Able to Become Pregnant (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Novo Nordisk A/S | Recruiting ➔ Active, not recruiting

Enrollment closed • Genetic Disorders • Long-acting Reversible Contraceptives • Obesity

Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity (GlobeNewswire) - P1b/2a | N=125 | NCT06064006 | Sponsor: Novo Nardisk A/S | "Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin...The primary endpoint was treatment emergent adverse events. The safety profile of amycretin was consistent with incretin-based therapies. The most common adverse events with amycretin were gastrointestinal and the vast majority were mild to moderate in severity. When evaluating the effects of treatment if all people adhered to treatment1 from a mean baseline body weight of 92.7 kg, people treated with amycretin achieved an estimated body weight loss of 9.7% on 1.25mg (20 weeks), 16.2% on 5mg (28 weeks) and 22.0% on 20mg (36 weeks). People treated with placebo experienced an estimated 1.9%, 2.3% and 2.0% body weight gain, respectively."

P1/2 data • Metabolic Disorders • Obesity

A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function (clinicaltrials.gov) - P1 | N=42 | Recruiting | Sponsor: Novo Nordisk A/S | Not yet recruiting ➔ Recruiting

Enrollment open • Diabetes • Genetic Disorders • Metabolic Disorders • Obesity • Renal Disease • Type 2 Diabetes Mellitus

A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin (clinicaltrials.gov) - P2 | N=125 | Completed | Sponsor: Novo Nordisk A/S | Recruiting ➔ Completed

Trial completion • Genetic Disorders • Obesity

A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin (clinicaltrials.gov) - P2 | N=120 | Recruiting | Sponsor: Novo Nordisk A/S | Phase classification: P1 ➔ P2 | N=84 ➔ 120

Enrollment change • Phase classification • Genetic Disorders • Obesity

A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the Skin (clinicaltrials.gov) - P1 | N=84 | Recruiting | Sponsor: Novo Nordisk A/S | Phase classification: P1/2 ➔ P1

Phase classification • Genetic Disorders • Obesity